KLHL18

Across TCGA pan-cancer cohorts, KLHL18 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated KLHL18 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher KLHL18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KLHL18 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, ESCA, and LUAD are the cancer types where KLHL18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
ESCA	DFS	Median	All	0.045	0.533	<.001	12	view →
LUAD	OS	Median	III,IV	0.158	0.663	.008	12	view →
UCEC	DFS	Median	All	0.974	0.827	.015	12	view →
BLCA	OS	Median	IV	0.153	0.599	.018	9	view →
COAD	DFS	Median	All	0.417	0.795	.023	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

KLHL18–DLBC (OS)

Open the DLBC breakdown →